Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 15 von 29
The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-11, Vol.5 (6), p.1757-1759
2017
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Home-based induction of sustained unresponsiveness in children with mild reactions to high doses of peanut
Ist Teil von
  • The journal of allergy and clinical immunology in practice (Cambridge, MA), 2017-11, Vol.5 (6), p.1757-1759
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2017
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • Few children with peanut allergy develop oral tolerance to peanut1,2 but 50% of children with peanut allergy do not react during formal oral food challenge (OFC) until they receive a cumulative eliciting dose of more than 100 mg peanut.3 These “low-dose–tolerant” patients have received no specific medical attention to date, which is focused on the “low-dose–sensitive” subjects.4-6 “Low-dose–tolerant” peanut-allergic children receive the standard advice about peanut avoidance (total avoidance) and epinephrine (constant availability), despite their demonstrated tolerance of low to moderate doses. The clinical team felt that this decision was appropriate and safe and was also ethical under the circumstances that these families literally could not wait for a formalized research protocol to be developed that included “low-dose–tolerant, high-dose–mild” children like theirs. [...]it was considered within the reasonable scope of an off-label practice to offer this clinical service to these patients. OIT for food allergy shows promising results; however, it is costly and resource intensive. [...]at present OIT is aimed mainly/exclusively at patients who demonstrate reactivity to low doses of peanut. Patient details Withdrew∗ (n = 6) Desensitized (n = 2) Sustained unresponsiveness (n = 8) Demographic characteristics Males 4 0 5 Current age (y) 11 (8.5-12.75) 8.5 (7-8.5) 12.5 (9.25-14) Comorbidities, n (%) Eczema 6 (100) 2 (100) 6 (75) Asthma 5 (83) 1 (50) 5 (62) Hayfever 4 (66) 0 (0) 3 (37) History of other food allergies 3 (50) 1 (50) 6 (75) Family history of atopy 4 (66) 1 (50) 7 (87) Allergy workup Age at first reaction (y) 5 (1.93-8.53) 1.2 (1.2-1.2) 4.3 (1.63-6.63) Peanut specific IgE (KUA/L) 6.8 2.9 2.39 rAra h2 specific IgE (KUA/L) 4.65 3.5 1.2 Maximum skin prick test (mm) (before age at program entry) 9 8.5 8 Table I Demographic characteristics, comorbidities, and diagnostic investigations according to group Group Patient no.
Sprache
Englisch
Identifikatoren
ISSN: 2213-2198
eISSN: 2213-2201
DOI: 10.1016/j.jaip.2017.03.027
Titel-ID: cdi_proquest_miscellaneous_1894521799

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX